Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Inspyr Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.01.
Current Consensus is
The current consensus among 0 polled investment analysts is to n/a stock in Inspyr Therapeutics. This N/A consensus rating has held steady for over two years.
Inspyr Therapeutics, Inc., a pharmaceutical company, focuses on the research and development of therapeutics for the treatment of cancer. Its immune-oncology lead asset is RT-AR001, an adenosine A2B receptor antagonist for tumor infiltration. The company was formerly known as GenSpera Inc. and changed its name to Inspyr Therapeutics, Inc. in August 2016. Inspyr Therapeutics, Inc. was incorporated in 2003 and is based in Westlake Village, California.